Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.
Highlights this week included:
Federal Circuit affirms invalidity of Teva’s patent on Rosuvastatin formulation: Teva v AstraZeneca (Orange Book Blog) (Patently-O) (IPBiz)
Pfizer’s Lipitor: A new model for delaying the effects of patent expiration (Patent Docs) (IPBiz)
Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.
General
WTO General Council extends deadline for TRIPS health amendment (IP Watch)
Australia: The gene patents debate in Australia – An update (Patent Docs)
India: A look at The Draft National Pharmaceuticals Policy, 2011 (Spicy IP)
Israel: If pigs had wings or, is the Israeli generic drug industry about to ambush the Patent Statute? Proposals waiting in the wings of the 18-Month Publication Bill (America-Israel Patent Law)
Spain: Ex parte preliminary injunctions in the pharmaceutical sector (Kluwer Patent Blog)
UK: Government will propose patent law changes to avoid infringements during pharma testing (Out-Law)
US: FDA proposes biosimilar and interchangeable biological product user fee system and performance goals (FDA Law Blog)
US: Senator Brown proposes modifications to the de novo process (FDA Law Blog)
US: Exclusive licenses do not discourage follow on research (BIOtechNOW)
US: Forthcoming article: Patentable subject matter for diagnostic methods after in re Bilski (Patently-O)
US: Supreme Court to hear oral arguments in two important cases this week: Caraco v. Novo Nordisk & Mayo Collaborative Services v. Prometheus (Pharma Patents)
Products
Crestor (Rosuvastatin) – US: Federal Circuit affirms invalidity of Teva’s patent on Rosuvastatin formulation: Teva v AstraZeneca (Orange Book Blog) (Patently-O) (IPBiz)
FCM1000 device – US: AntiCancer files patent infringement suit against Leica Microsystems (Patent Docs)
Glivec (Imatinib) – India: Novartis hearing postponed to February (IP Watch)
Lipitor (Atorvastatin) – US: Pfizer’s Lipitor: A new model for delaying the effects of patent expiration (Patent Docs) (IPBiz)
Lysteda (Tranexamic) – US: Ferring files patent infringement suits against Watson and Apotex following Para IV challenge (Patent Docs)
Magnesium esomeprazole – UK: Construction of “Swiss” medical use claims in Europe: Ranbaxy v AstraZeneca (Patent Docs)
Prandin (Repaglinide) – US: Supreme Court to hear oral arguments in two important cases this week: Caraco v. Novo Nordisk & Mayo Collaborative Services v. Prometheus (Pharma Patents)
Ritalin (Methylphenidate) – US: FDA proposes to depart from conventional bioequivalence metrics; Draft guidance proposes partial AUC for generic Ritalin LA (FDA Law Blog)
Sprycel (Dasatinib) – US: Bristol-Myer Squibb files patent infringement suit against Apotex following Para IV certification filing (Patent Docs)